Adverse reactions to COVID‐19 vaccines: A practical approach

COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccines are approved in the United Kingdom with many more in deve...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & Experimental Allergy 2021-06, Vol.51 (6), p.770-777
Main Authors: Rutkowski, Krzysztof, Mirakian, Rita, Till, Stephen, Rutkowski, Ryszard, Wagner, Annette
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - adverse effects
Algorithms
Allergies
Anaphylaxis
Anaphylaxis - chemically induced
Anaphylaxis - diagnosis
Anaphylaxis - therapy
Clinical Decision-Making
COVID-19
COVID-19 - diagnosis
COVID-19 - immunology
COVID-19 Drug Treatment
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Decision Support Techniques
Drug Hypersensitivity - diagnosis
Drug Hypersensitivity - etiology
Drug Hypersensitivity - therapy
Humans
Review
Risk Assessment
Risk Factors
Treatment Outcome
Vaccination - adverse effects
Vaccine Excipients - adverse effects
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccines are approved in the United Kingdom with many more in development. There are limited data on the triggers and mechanisms of anaphylaxis to these vaccines. We review the potential allergenic compounds in the COVID‐19 vaccines and describe an innovative allergy support model for the vaccination hubs that allows most patients with severe allergy be immunized. Finally, we propose a practical algorithm for the investigations of anaphylaxis to these vaccines.
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.13880